Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | ESRRB | O95718 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2756803 | 0.91 | CYP1A2 (0.39) | AKR1C3AKR1C2CYP1A2CYP2A6ESRRB | |
| SCHEMBL2705599 | 0.91 | KDM4E (0.35) | ESRRBESRRAMAPTKDM4EMEN1 | |
| SCHEMBL2756788 | 0.85 | DHODH (0.36) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL15500326 | 0.85 | DHODH (0.36) | CYP1A2CYP2A6ESRRBESRRAMAPT | |
| SCHEMBL18462405 | 0.82 | MEN1 (0.32) | MAPTKDM4EMEN1USP2CYP3A4 | |
| SCHEMBL2705798 | 0.82 | LMNA (0.35) | ESRRBESRRAMAPTKDM4EMEN1 | |
| SCHEMBL9980283 | 0.82 | ESRRB (0.39) | AKR1C3AKR1C2CYP1A2CYP2A6ESRRB | |
| SCHEMBL2756468 | 0.77 | LMNA (0.35) | CYP1A2CYP2A6MAPTKDM4EMEN1 | |
| SCHEMBL15463302 | 0.77 | ESRRB (0.36) | CYP1A2CYP2A6ESRRBESRRAMAPT | |
| SCHEMBL9980128 | 0.75 | LMNA (0.35) | CYP1A2CYP2A6MAPTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981955-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2010132601-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | AKR1C3 4082/4885AKR1C2 4102/4885CYP1A2 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.